Bevacizumab Against Recurrent Retinal Detachment

Bevacizumab Against Recurrent Retinal Detachment

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Inclusion Criteria:

• Age ≥ 18 years
• Eyes with rhegmatogenous retinal detachment

Exclusion Criteria:

• Presence of PVR
• Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
• Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
• Secondary retinal detachment repair
• Use of silicone oil as tamponade agent
• Patients less than 18 years of age
• Pregnancy
• Known allergy or contraindication to intravitreal bevacizumab